Arvinas, a clinical-stage biotech company specializing in targeted protein degradation therapies, will announce its third quarter 2026 financial results on November 3, 2026. The company will also provide a corporate update during a live webcast accessible on its website. Arvinas is advancing multiple drug candidates for serious diseases, including cancer and neurodegenerative disorders, and is known for developing the first FDA-approved PROTAC drug with Pfizer. Investors and interested parties can watch the webcast live or access a replay afterward on Arvinas' site.
Arvinas' upcoming Q3 2026 financial results provide context for the Health sector's current market snapshot on Pluang as of Oct 27, 2026, 17:02 WIB: Among 150 priced Health-sector US stocks, 60 rose and 78 fell today. ACAD (ACADIA Pharmaceuticals Inc.) stood out with a 2.74% gain and 100% buy order activity, contrasting with TNGX (Tango Therapeutics Inc.) which dropped 2.64% and had 14% sell orders. ALMS (Alumis Inc.) also gained 2.92%, with a typical hold time of 12 days on Pluang.
Black Ore introduced Black Ore for Small Firms, an AI-powered tax automation platform designed for small to mid-sized accounting practices. It integrates with Intuit tax software, enabling firms to handle more clients without increasing staff by auto...
Alm. Brand A/S executed a share buy-back program from October 20 to 26, 2026, purchasing 1.81 million shares at an average price of DKK 17.41 each. This brings the total shares bought under the program to nearly 19.58 million, costing about DKK 324 m...
Hyphenate, an autonomous finance platform, secured $45 million in Series A funding following an 86-fold revenue increase and an 11-fold growth in customers over 12 months. Its AI-driven agents now handle 90% of routine finance work, such as invoicing...
CareCloud has named Mitchell Brie as Chief Compliance Officer to lead its growing healthcare compliance business. Brie, founder of Empower Healthcare & Compliance Partners (acquired by CareCloud), will oversee corporate compliance and continue as Pre...
Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...
